Heparīna Nātrijs Panpharma

Heparīna Nātrijs Panpharma is a prescription anticoagulant that contains the active ingredient heparin sodium. It is supplied in an injectable form for intravenous administration and conforms to EU pharmaceutical standards. The product is used to inhibit clot formation by enhancing antithrombin III activity, providing therapeutic anticoagulation in various clinical settings.

Heparīna Nātrijs Panpharma is indicated for several antithrombotic purposes in hospital and procedural environments.

- Prevention and treatment of venous thromboembolism (VTE) - Prophylaxis of deep vein thrombosis (DVT) in patients undergoing surgery - Management of acute coronary syndromes, including unstable angina - Prevention of clot formation in extracorporeal circuits such as dialysis or cardiopulmonary bypass - Adjunct therapy during percutaneous coronary interventions (PCI)

Adverse reactions to Heparīna Nātrijs Panpharma can vary in frequency and severity.

Common: - Minor bleeding at injection site - Hematuria (blood in urine) - Epistaxis (nosebleed) - Gastrointestinal discomfort - Elevated liver enzymes

Serious: - Heparin-induced thrombocytopenia (HIT) - Major hemorrhage (intracranial, gastrointestinal) - Allergic reactions including anaphylaxis - Spontaneous bleeding into joints or muscles

When prescribing Heparīna Nātrijs Panpharma, clinicians should consider several safety factors.

- Assess baseline coagulation status and platelet count before initiation - Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels during therapy - Use caution in patients with a history of heparin-induced thrombocytopenia - Adjust dose in renal or hepatic impairment as needed - Avoid use in active major bleeding or uncontrolled hypertension - Counsel patients on signs of bleeding and when to seek medical attention

Heparīna Nātrijs Panpharma may interact with other agents that affect hemostasis.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring - Thrombolytic agents such as alteplase or streptokinase - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk

Use with caution: - Antiplatelet drugs (e.g., clopidogrel, ticagrelor) - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents - Glycoprotein IIb/IIIa inhibitors used during cardiac procedures